.png)
In this series of blogs we have established that central sleep apnoea (CSA) may affect up to 1:5 individuals with OSA (1). And we have also established that this is a clinically relevant and important consideration for patients with concomitant OSA/CSA as these individuals may often have a higher symptom burden (1).
Failing to distinguish between central and obstructive hypopneas can lead to an underestimation of the severity of central sleep-disordered breathing. This oversight may result in misguided treatment decisions and could hinder the expected improvements in quality of life and daytime sleepiness for patients receiving personalised care CSA (1).
Not all CPAP algorithms are equal in detecting events during leaks.
As has been demonstrated by Midlet et al in 2021 (2). In a bench test they found a notable variation in the reported residual apnea-hypopnea index (AHI) among different CPAP brands under certain leak conditions. For some patients, switching CPAP brands could significantly affect their reported residual AHI. In this same study the brand C CPAP device is the S Box which reports all residual central hypopnoeas compared to Brand A which does not report central hyponoeas (2). This may result in a significant number of patients who develop treatment emergent CSA being overlooked (1:5) as reported by Pepin et al 2024 in a large "real life study" (1).
The S Box was more reliable than other devices in its response to leaks compared to other devices in this bench test. Sleep medicine clinicians should be alerted to the differences between brands and learned societies should push for standardisation of AHI reporting.
Discover Néa
Let’s take a closer look at the rationale and innovation behind Néa and how it sets a new benchmark in CPAP technology.
The Néa CPAP uses a modified S Box algorithm which allows it to function in the same way in the calculation of exact leak flows but Néa can also be customised to assist some patients if they are having trouble with aspects of adherence to therapy.
Sefam's Néa algorithm accurately measures all residual obstructive and central hypopnoea events unlike other devices.
Sefam Connect displays residual CSA events:
Sefam's Néa algorithm responds to the precise calibrated leak of any mask which can be entered at the start of therapy or when changing between any mask type. The precise leak of each mask type can be entered in the clinical menu of the device or remotely in Sefam Connect allowing precise calculation of residual leak.
Accurate Circuit Calibration is also possible so that the prescribed CPAP pressure = the delivered pressure at the mask interphase.
Safety and silence:
Néa is the global first and the only CPAP device without sound abatement foam in the patient airway pathway. The Néa range is equipped with our latest patented Néalveole® technology. The hexagonal shape of the honeycomb is effective at dampening vibrations. When sound waves enter the honeycomb structure, energy is dispersed reducing the amplitude of the vibration and noise.
Néa the FIRST of its kind in the global market.
Key Benefits of Nea’s Foam-Free Design:
Safety First: With no foam.
Long-Lasting Durability: Néa's materials and structure are designed for longevity.
Quiet Operation: The innovative design ensures noise reduction.
Néa is the only CPAP device that accurately records residual CSA thanks to its algorithm and many standout design features.
Néa - a new world paradigm in CPAP therapy.
Comments